<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00043797</url>
  </required_header>
  <id_info>
    <org_study_id>676/US/2-01</org_study_id>
    <nct_id>NCT00043797</nct_id>
  </id_info>
  <brief_title>Lidorestat (IDD 676) for the Treatment of Diabetic Neuropathy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Institute for Diabetes Discovery, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Institute for Diabetes Discovery, LLC</source>
  <brief_summary>
    <textblock>
      This clinical trial is to determine an effective dosage and to study the safety of an&#xD;
      investigational drug -lidorestat (IDD-676)- which is intended to stop or slow the progression&#xD;
      of diabetic peripheral neuropathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic peripheral neuropathy is one of the most important and serious complications of&#xD;
      diabetes. It can cause pain and loss of sensation, loss of mobility and lead to chronic&#xD;
      wounds and amputations. Studies indicate 50% or more of people who have diabetes now have or&#xD;
      will have significant neuropathy.&#xD;
&#xD;
      Several currently marketed or investigational drugs are available to treat the painful&#xD;
      symptoms of diabetic peripheral neuropathy, but there are no approved drugs that have been&#xD;
      shown to prevent or slow the progression of the neuropathy itself.&#xD;
&#xD;
      The current clinical trial is an early phase II study designed to investigate the safety of&#xD;
      the investigational drug lidorestat (IDD-676) and to determine the effect of various dose&#xD;
      levels on important biochemical processes in the pathology of diabetic neuropathy.&#xD;
&#xD;
      Participants who enter and complete this study will, if the agent is successful, help in a&#xD;
      very important way to bring an effective treatment from research laboratories to widespread&#xD;
      availability for treatment. On the basis of the results of this study, large scale studies&#xD;
      will be undertaken to support application for product registration and distribution in the&#xD;
      U.S. and other countries throughout the world.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Diabetic Polyneuropathy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidorestat (IDD 676)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:&#xD;
&#xD;
          -  Clinical diagnosis of Type 1 or Type II diabetes with mild to moderate diabetic&#xD;
             peripheral neuropathy.&#xD;
&#xD;
          -  Healthy status except for diabetes&#xD;
&#xD;
          -  Ability to make frequent clinic visits over a 7-month period.&#xD;
&#xD;
          -  Willingness and ability to understand and sign consent form.&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Presence of uncontrolled hypertension&#xD;
&#xD;
          -  History or presence of significant kidney or liver disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Scottsdale Medical Specialists</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glendale Adventist Medical Center</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marin Endocrinology Associates</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes &amp; Endocrine Associates</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami, Dept. of Diabetes, Endocrinology &amp; Metabolism</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University - School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brody School of Medicine, East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas, Southwest Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes &amp; Glandular Disease Clinic</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital, University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de L'Enfant-Jesus</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.idd-diabetes.com</url>
    <description>Click here for more information on this study:</description>
  </link>
  <link>
    <url>http://www.diabetes.org</url>
    <description>Click here for more information on diabetes and diabetic neuropathy</description>
  </link>
  <verification_date>December 2002</verification_date>
  <study_first_submitted>August 13, 2002</study_first_submitted>
  <study_first_submitted_qc>August 14, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2002</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>ARI</keyword>
  <keyword>Diabetic polyneuropathy</keyword>
  <keyword>Diabetic complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

